Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation
Transplantation Proceedings · 2026
DOI: 10.1016/j.transproceed.2025.12.008 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Transplantation Proceedings, 2026. Verfasst von Haein Kim und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Cellular Therapy, Cedars-Sinai Medical Center, Los Angeles, CA. Hauptthemen laut MEDLINE: Cyclophosphamide, Graft vs Host Disease, Immunosuppressive Agents, Hematopoietic Stem Cell Transplantation. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: Post-transplant cyclophosphamide (PTCy) was developed to allow the use of haploidentical donors for allogeneic stem cell transplantation (alloHSCT), then tested with matched donors. Cedars-Sinai Medical Center Blood and Marrow Transplant was an early adopter of PTCy for matched alloHSCT in 2016. PURPOSE OF THE RESEARCH: We retrospectively analyzed 15-year outcomes of patients who underwent alloHSCT with matched donor stem cells prior to 2016 (n = 252), with the outcomes of patients who were transplanted in the PTCy era, post-2016 (n = 99), to assess the impact of the switch to PTCy, while controlling for other differences between the cohorts. PRINCIPLE RESULTS: Overall Survival (OS) was better in the PTCy group (at 1 year, 90% vs 62%, P < .0001), and the difference persisted in OS at 2 years and 3 years. There was no difference in relapse (26% non-PTCy vs 19% PTCy; P = .3560). Non-relapse mortality was lower with PTCy, 7% vs 22% without, P = .0002. Acute GVHD was lower in the PTCy group (16% PTCy vs 33% non-PTCy, P = .0013). Chronic GVHD was similar between the two groups, 35% in the PTCy group and 42% in the non-PTCy group (P = .1235), but the rate of extensive cGVHD was lower, 15% with PTCy vs 29% without; P = .0078. Post-transplant hospital stay was shorter, 23 ± 13.1 days in the non-PTCy group and 18 ± 7.0 days with PTCy, P < .0001. CONCLUSIONS: Long-term follow up of patients transplanted using PTCy with matched donors has demonstrated superiority of PTCy compared to tacrolimus methotrexate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Hematology and Cellular Therapy, Cedars-Sinai Medical Center, Los Angeles, CA.
- Department of Pharmacy, Cedars-Sinai Medical Center, Los Angeles, CA.
- Miami Cancer Institute at Baptist Health, Inc., Miami, FL.
- Transfusion Medicine, Cedars Sinai Medical Center, Los Angeles, CA.
- Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, CA.
- Hematology and Cellular Therapy, Cedars-Sinai Medical Center, Los Angeles, CA. Electronic address: Noah.merin@cshs.org.
Zitieren
APA
Kim, H., Merchant, A., Darrah, J., Sasine, J., Lee, H., Vescio, R., Oveisi, D., McGalliard, B., Linhares, Y., Rejali, A., Van Strein, P., Klapper, E., Hekimian, B., Chute, J., Paquette, R., & Merin, N. (2026). Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.12.008
Vancouver
Kim H, Merchant A, Darrah J, Sasine J, Lee H, Vescio R, et al. Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation. Transplantation Proceedings. 2026. doi:10.1016/j.transproceed.2025.12.008
BibTeX
@article{Kim2026,
author = {Kim, Haein and Merchant, Akil and Darrah, Justin and Sasine, Joshua and Lee, Hannah and Vescio, Robert and Oveisi, David and McGalliard, Brittany and Linhares, Yuliya and Rejali, Ali and Van Strein, Patricia and Klapper, Ellen and Hekimian, Behrooz and Chute, John and Paquette, Ron and Merin, Noah},
title = {Single Center Retrospective Comparison of Post-Transplant Cyclophosphamide and Standard Graft-Versus-Host Disease Prophylaxis in Matched Donor Allogeneic Transplantation},
journal = {Transplantation Proceedings},
year = {2026},
doi = {10.1016/j.transproceed.2025.12.008}
}
EUVIMED